Comparisons of pharmacokinetics of glimepiride in combination with Ojeok-san ver...

연구 요약

Comparisons of pharmacokinetics of glimepiride in combination with Ojeok-san versus glimepiride alone: an open-label, one-sequence, two-treatment controlled clinical study.

Scientific reports 학술지에 발표된 이 연구는 Kim J, Kwon M, Lee S 외 연구팀이 수행하였습니다.

이 연구는 'Comparisons of pharmacokinetics of glimepiride in combination with Ojeok-san versus glimepiride alone: an open-label, one-sequence, two-treatment controlled clinical study.'에 대한 과학적 분석을 제공합니다.

핵심 내용

Glimepiride remains a cost-effective antidiabetic treatment despite its potential risks. However, its interaction with traditional medicines like Ojeok-san (OJS), a commonly used herbal medication, warrants investigation. This open-label, fixed-sequence, two-period, two-treatment crossover study involved 17 healthy male volunteers. Subjects received glimepiride 4 mg once daily for 2 days in period 1, followed by OJS 4.35 g three times daily for 8 days, with concurrent glimepiride administration on the final two days in period 2. Co-administration of OJS with glimepiride resulted in pharmacokinetic changes. The mean area under the plasma concentration-time curve (AUC) from dosing to 24 h post-dosing (AUC0-24 h) of glimepiride decreased from 1283.53 ng∙h/mL to 1125.27 ng∙h/mL, and the mean maximum concentration (Cmax) reduced from 250.76 ng/mL to 209.38 ng/mL when compared to glimepiride alone. OJS co-administration also prolonged the median time to reach maximum concentration (Tmax) and half-life (t1/2). The study demonstrated pharmacokinetic interactions between glimepiride and OJS, showing reduced systemic exposure and altered elimination patterns of glimepiride during co-administration.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 40670458)

📄 [전문 보기 (Markdown)](fulltext/40670458-comparisons-of-pharmacokinetics-of-glimepiride-in-combinatio.md)